Clinical trials: Penile Cancer, active
Squamous Cell Carcinoma of the Penis, Usual Type
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment.
- Trial name
- InPACT (NCT02305654)
- Testing
- ILND - Inguinal Lymph Node Dissection, Paclitaxel, Ifosfamide
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Erectile Dysfunction Following Radical Prostatectomy
PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)
The PEHAB-II study is prospective, randomized trial designed to assess the effect of two different rehabilitation strategies on the recovery of erectile function in nerve sparing prostatectomy patients.
- Trial name
- PEHAB-II (NCT06875258)
- Testing
- Sildenafil, Erectile vacuum device
- Where
- 3 sites in Netherlands
- Volunteers
- 198 people
- Sponsor
- The Netherlands Cancer Institute
Penile Cancer, Squamous Carcinoma
Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis
Squamous cell carcinoma of the penis is a rare tumor in Europe, whose prognosis and survival are influenced by metastatic lymph node involvement. Its frequency in France is estimated at less than 1% of human cancers.
- Trial name
- MEGACEP (NCT02817958)
- Testing
- Chemotherapy TIP
- Where
- 17 sites in France
- Volunteers
- 37 people
- Sponsor
- UNICANCER
Penile Squamous Cell Carcinoma (PSCC)
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
The DEPECA-1 trial is the first systematic Phase II trial to evaluate response and survival to a combination of antibody-drug conjugate enfortumab vedotin plus the PD-L1 inhibitor avelumab in patients with locally advanced and…
- Trial name
- NCT07110038
- Testing
- Avelumab, enfortumab vedotin
- Where
- 9 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
HPV-Related Carcinoma, HPV-Related Cervical Carcinoma
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
The study will consist of two parts : In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 participants at increasing doses of TG4001 in combination with avelumab according to a 3+3 design.
- Conditions
- HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma
- Trial name
- NCT03260023
- Testing
- TG4001, Avelumab
- Where
- 20 sites in United States, France and 1 more
- Volunteers
- 143 people
- Sponsor
- Transgene
HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
This is a phase 1/2, open-label, single arm, multicenter study in patients with advanced or metastatic HPV16- or HPV52-positive carcinomas who have progressed after at least one line of systemic therapy, including but not limited…
- Conditions
- HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma
- Trial name
- NCT06505551
- Testing
- SCG142, Cyclophosphamide, Fludarabine
- Volunteers
- 66 people
- Sponsor
- SCG Cell Therapy Pte. Ltd.
Human Papillomavirus Associated Carcinomas, Cervical Cancer
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
- Conditions
- Human Papillomavirus Associated Carcinomas, Cervical Cancer, Head and Neck Cancers, Anal Cancer
- Trial name
- NCT06544720
- Testing
- SCG142 TCR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body.
- Conditions
- Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma
- Trial name
- NCT02721732
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- M.D. Anderson Cancer Center
Paget Disease, Extramammary, Rhabdomyosarcoma
Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors
The goal of this clinical trial is to learn if albumin-paclitaxel, ifosfamide and cisplatin (Nab-TIP) works to treat advanced rare tumors including PAGET's disease of scrotum with infiltrating sweat gland carcinoma （cohort 1）…
- Conditions
- Paget Disease, Extramammary, Rhabdomyosarcoma, Testicular Cancer, Penile Cancer
- Trial name
- NCT06684327
- Testing
- Albumin-paclitaxel Injection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Penile Cancer
The Role of Functional Magnetic Resonance Imaging in Preoperative Assessment of Primary Penile Carcinoma
The proposed project is intended as a prospective study that includes 60 patients with newly diagnosed penile squamous cell carcinoma (SCC) referred to Oslo University Hospital (OUH), Radiumhospitalet, for surgery, primarily…
- Trial name
- NCT05447273
- Testing
- Multi-parametric, functional magnetic resonance imaging (MRI)
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Oslo University Hospital
Prostate Cancer, Urinary Incontinence
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
This study is being done at Duke Health and includes adult men who have been treated for localized prostate cancer. The goal is to see if it is feasible and acceptable to offer sex therapy by telehealth after prostate cancer…
- Conditions
- Prostate Cancer, Urinary Incontinence, Erectile Dysfunction
- Trial name
- RESTORE-PC (NCT07685249)
- Testing
- Sex Therapy, Pelvic Floor Physical Therapy, Vacuum Erection Device (VED)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Duke University
Kallmann Syndrome, Hypogonadotropic Hypogonadism
Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate
The purpose of this study is to explore the genetic basis of reproductive disorders and cleft lip and/or palate.
- Conditions
- Kallmann Syndrome, Hypogonadotropic Hypogonadism, Hypothalamic Amenorrhea, Polycystic Ovarian Syndrome
- Trial name
- NCT01601171
- Where
- Switzerland
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Survivorship, Prostate Cancer
Linking In With Advice and Supports for Men Impacted by Metastatic Cancer
To evaluate the feasibility of introducing a men's cancer survivorship programme into routine follow up care in patients with advanced genitourinary malignancies.
- Conditions
- Survivorship, Prostate Cancer, Kidney Cancer, Urothelial Tract/Bladder Cancer, Nos
- Trial name
- LIAM Mc (NCT05946993)
- Testing
- Physiotherapy, Dietitian Support, Nursing and Psychosocial
- Where
- Ireland
- Volunteers
- 72 people
- Sponsor
- University College Cork
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
This phase III clinical trial was designed to evaluate the efficacy, immunogenicity and safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) manufactured by Xiamen…
- Conditions
- Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Penile/Perianal/Perineal Cancer, Anal Cancer
- Trial name
- NCT06866574
- Testing
- Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli), Aluminum Adjuvant
- Where
- 4 sites in China
- Volunteers
- 9,300 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Penile Cancer, Inguinal Lymphadenopathy
VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer
Assess the feasibility of performing a RCT comparing videoendoscopic radical inguinal lymphadenectomy versus open radical inguinal lymphadenectomy in men diagnosed with genital cancer requiring inguinal lymphadenectomy, and…
- Conditions
- Penile Cancer, Inguinal Lymphadenopathy, Melanoma
- Trial name
- VELRAD (NCT05592639)
- Testing
- Videoendoscopic radical inguinal lymphadenectomy or open radical inguinal lymphadenectomy
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Penile Squamous Cell Carcinoma, Metastatic Penile Squamous Cell Carcinoma
Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer
This is a single-arm, Phase 2 clinical trial (PERSEUS TRIAL / LACOG 1924) evaluating the efficacy, safety, and tolerability of sacituzumab tirumotecan (sac-TMT; MK-2870) as a second-line treatment for patients with advanced or…
- Trial name
- PERSEUS (NCT07815197)
- Testing
- Sacituzumab Tirumotecan
- Where
- 11 sites in Brazil
- Volunteers
- 37 people
- Sponsor
- Latin American Cooperative Oncology Group
Colorectal Cancer, Breast Carcinoma
FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer
This trial is a first in human (FIH) clinical trial in patients with Colorectal cancer (CRC) after failure of at least three lines of previous therapy aiming to evaluate safety and efficacy of CC-3, a bispecific antibody (bsAb)…
- Conditions
- Colorectal Cancer, Breast Carcinoma, Sarcoma, Penile Carcinoma
- Trial name
- CoRe_CC-3 (NCT05999396)
- Testing
- Administration of CC-3
- Where
- Germany
- Volunteers
- 89 people
- Sponsor
- German Cancer Research Center
Head and Neck Cancer, Cervical Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
- Trial name
- NCT05973487
- Testing
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201
- Where
- 21 sites in United States
- Volunteers
- 840 people
- Sponsor
- TScan Therapeutics, Inc.
Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Background: Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough people to conduct large trials for new treatments.
- Conditions
- Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder, Squamous Cell Carcinoma of the Urinary Tract
- Trial name
- NCT06161532
- Testing
- Sacituzumab govitecan, Atezolizumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)